A Multi-Center, Randomized, Double-Blind, Placebo/Active-Controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of HSK21542 Injection for Postoperative Pain Treatment
Latest Information Update: 06 Apr 2023
Price :
$35 *
At a glance
- Drugs HSK 21542 (Primary) ; Tramadol (Primary)
- Indications Postoperative pain
- Focus Registrational; Therapeutic Use
- Sponsors Haisco Pharmaceutical Group
- 03 Apr 2023 Status changed from recruiting to completed.
- 09 Feb 2023 Planned number of patients changed from 285 to 387.
- 09 Feb 2023 Planned End Date changed from 1 Mar 2023 to 30 Jun 2023.